Top Markets
#1 Helium Helium +52.72%
#2 Seeker Seeker +50.59%
#3 Pons Pons +35.63%
#4 UnifAI Network UnifAI Network +31.30%
#5 Zylo Ecosystem Zylo Ecosystem +25.79%
#6 VVS Finance VVS Finance +24.87%
#7 TENDIES TENDIES +19.47%
#8 Bounce Bounce +17.09%
#9 Tensor Tensor +15.98%
#10 Songbird Songbird +15.53%
Coin of the day
Helium Helium
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rang în acțiuni #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Preț acțiune
$9.50
Ultima sincronizare: 2025-01-08
Capitalizare de piață
$819.52M
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Poseida Therapeutics, Inc. (PSTX)

Categorie

Healthcare
Raport P/B pentru Poseida Therapeutics, Inc. (PSTX)
Raport P/B la data de August 2026 TTM: 8.26
Conform celor mai recente rapoarte financiare și prețului acțiunilor Poseida Therapeutics, Inc., raportul P/B actual (TTM) este 8.26. La sfârșitul anului 2022, compania avea un P/B de 2.03.
Istoricul raportului P/B pentru Poseida Therapeutics, Inc. din 2016 până în 2026
Raport P/B la sfârșitul fiecărui an
An Raport P/B Schimbă
2026 (TTM) 8.26 182.94%
2023 2.92 43.83%
2022 2.03 -25.05%
2021 2.71 10.84%
2020 2.45 -159.95%
2019 -4.08 -43.25%
2018 -7.19 -60.46%
2017 -18.18 -132.79%
2016 55.46 0.00%
Raport P/B pentru companii similare sau competitoare
Companie Raport P/B Diferență raport P/B Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -23.24%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -24.46%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -69.67%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -55.11%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH